ent goals. As a CRO, Symbio's main area of therapeutic expertise is dermatology. Symbio has managed over 30 Phase II-IV trials in almost every dermatology indication. In addition, Symbio has managed projects in ophthalmology, women's health, and osteoarthritis indications. Capabilities include full project management, monitoring, data management, statistics and report writing. Efficient, cost effective services are provided to clients by a staff that has a wealth of industry experience in clinical research. Experts include PhD statisticians, a full-time medical writer, and a full-time MD. Symbio's extensive network of clinical research sites, based on relationships developed over the years, results in fast study start-up and turnaround.
Symbio's Phase I-IV clinical site is located within St. Anthony Memorial Hospital in Michigan City, IN. The hospital has dedicated an entire floor to the Symbio site. The site is a 62 bed capacity unit with state-of-the-art medical equipment. There is an on-site pharmacy and laboratory which can turn around many tests in 24 hours. There are 1500+ normal, healthy volunteers in the database. Symbio also has access to patient populations to recruit for any therapeutic area. The research team includes a full-time Medical Director and Director of Clinical Operations. Hospital physicians and specialists are available to collaborate with Symbio for studies. Experience includes, but is not limited to, standard PK studies, oncology, sensitization and irritation patch studies.
About DATATRAK International, Inc.
DATATRAK International, Inc. is a worldwide technology and services company focused on the provision of multi-component eClinical solutions and related services for the clinical trials industry. We operate under the concept of DATATRAK ONE(TM), which encompasses our unique, single platform technology. The singul
Page: 1 2 3 4 Related biology technology :1
|SOURCE DATATRAK International, Inc.|
Copyright©2009 PR Newswire.
All rights reserved
. DATATRAK International, Inc. to Release 2009 Second Quarter and First-Half Operating Results on August 17, 20092
. DATATRAK International, Inc. Forms Strategic Partnership with Inclinix, Inc.3
. Quantel Signs a Distribution Agreement With US-based National Biological4
. Global Med Technologies(R) Signs Binding LOI With European Company for Breakthrough Transfusion Safety RFID Product5
. Cell Biosciences Signs Agreement to Acquire Alpha Innotech6
. Fauve Intertrade Signs Major Energy Contracts in China7
. SynCo Bio Partners Enters the Japanese Market as it Signs its First Agreement With a Japanese Pharmaceutical Company8
. Martek Signs Sole-Source Supply Agreement with Milk Powder Solutions9
. Martek Signs Sole-Source ARA Supply Agreement with Puleva Food S.L.10
. Dendreon Signs Lease for New Manufacturing Facility in Atlanta11
. Alexandria Real Estate Equities, Inc. Signs Biopharmaceutical Company, Lilly, as Anchor New York City Tenant at the Alexandria Center for Science and Technology